Biostructural, biochemical and biophysical studies of mutant IDH1

We report bio-structural, bio-chemical and bio-physical evidence demonstrating how small molecules can bind to both wild-type and mutant IDH1, but only inhibit the enzymatic activity of the mutant isoform. Enabled through x-ray crystallography, we characterized a series of small molecule inhibitors that bound to mutant IDH1 differently than the marketed inhibitor Ivosidenib, for which we have determined the x-ray crystal structure. Across the industry several mutant IDH1 inhibitor chemotypes bind to this allosteric IDH1 pocket and selectively inhibit the mutant enzyme. Detailed characterization by a variety of biophysical techniques and NMR studies led us to propose how compounds binding in the allosteric IDH1 R132H pocket inhibit the production of 2-Hydroxy glutarate.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2024-09-09
DOI
https://doi.org/10.1038/s41467-024-51692-0
Citations
3
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.86
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biostructural, biochemical and biophysical studies of mutant IDH1

Michael Hon‐Wah Lam, Christian Fischer, S.M. Soisson, Mark A. McCoy et al.
3 citations
Nature Communications
Cancer, Hypoxia, and Metabolism
0.86
article

Biostructural, biochemical and biophysical studies of mutant IDH1

Michael Hon‐Wah Lam, Christian Fischer, S.M. Soisson, Mark A. McCoy, F Richard Miller, Jun Lü
article en
3 citations

Abstract

We report bio-structural, bio-chemical and bio-physical evidence demonstrating how small molecules can bind to both wild-type and mutant IDH1, but only inhibit the enzymatic activity of the mutant isoform. Enabled through x-ray crystallography, we characterized a series of small molecule inhibitors that bound to mutant IDH1 differently than the marketed inhibitor Ivosidenib, for which we have determined the x-ray crystal structure. Across the industry several mutant IDH1 inhibitor chemotypes bind to this allosteric IDH1 pocket and selectively inhibit the mutant enzyme. Detailed characterization by a variety of biophysical techniques and NMR studies led us to propose how compounds binding in the allosteric IDH1 R132H pocket inhibit the production of 2-Hydroxy glutarate.

Nature CommunicationsVol. 15(1)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Openalex Percentile: Top 26%
Cancer, Hypoxia, and Metabolism
0.86
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Biostructural, biochemical and biophysical studies of mutant IDH1 — Michael Hon‐Wah Lam, Christian Fischer, et al. · Nature Communications (2024) | TGRS Research Map | TGRS